open access

Vol 15, No 1 (2012)
Reviews
Published online: 2012-04-24
Submitted: 2012-04-26
Accepted: 2012-04-26
Get Citation

Metaiodobenzylguanidine scintigraphy of cardiac sympathetic innervation

Anna Teresińska
Nucl. Med. Rev 2012;15(1):61-70.

open access

Vol 15, No 1 (2012)
Reviews
Published online: 2012-04-24
Submitted: 2012-04-26
Accepted: 2012-04-26

Abstract

Metaiodobenzylguanidine (MIBG), a noradrenaline analogue,labelled with radioactive iodine I-123 is used for assessingpre-synaptic activity of the myocardial adrenergic system. Thepaper describes the mechanism of myocardial I-123-MIBG uptakeand the relevant examination methods. It also refers to thenecessity of standardising acquisition methods and assessmentcriteria in order to improve comparability of results, especiallynumerical results, originating from various countries and centres.Although first introduced as a cardiological diagnostic procedure30 years ago, I-123-MIBG myocardial scintigraphy continues tobe mostly applied as a research method, even though its diagnosticand/or prognostic importance, especially in the case ofheart failure, has been widely reported. The recently publishedresults of two extensive retrospective works and a major prospective,multi-centre international ADMIRE-HF study confirmedthat I-123-MIBG scintigraphy has a high independent prognosticvalue in evaluating patients with heart failure. Abnormalmyocardial I-123-MIBG uptake can also be indicative of higherrisk of ventricular arrhythmias and sudden cardiac death inpatients with heart failure. I-123-MIBG myocardial scintigraphyalso seems to have considerable potential for the detection anddifferentiation of neurodegenerative diseases.

Abstract

Metaiodobenzylguanidine (MIBG), a noradrenaline analogue,labelled with radioactive iodine I-123 is used for assessingpre-synaptic activity of the myocardial adrenergic system. Thepaper describes the mechanism of myocardial I-123-MIBG uptakeand the relevant examination methods. It also refers to thenecessity of standardising acquisition methods and assessmentcriteria in order to improve comparability of results, especiallynumerical results, originating from various countries and centres.Although first introduced as a cardiological diagnostic procedure30 years ago, I-123-MIBG myocardial scintigraphy continues tobe mostly applied as a research method, even though its diagnosticand/or prognostic importance, especially in the case ofheart failure, has been widely reported. The recently publishedresults of two extensive retrospective works and a major prospective,multi-centre international ADMIRE-HF study confirmedthat I-123-MIBG scintigraphy has a high independent prognosticvalue in evaluating patients with heart failure. Abnormalmyocardial I-123-MIBG uptake can also be indicative of higherrisk of ventricular arrhythmias and sudden cardiac death inpatients with heart failure. I-123-MIBG myocardial scintigraphyalso seems to have considerable potential for the detection anddifferentiation of neurodegenerative diseases.
Get Citation

Keywords

cardiac sympathetic innervation, scintigraphy, iodine-123 metaiodobenzylguanidine, MIBG

About this article
Title

Metaiodobenzylguanidine scintigraphy of cardiac sympathetic innervation

Journal

Nuclear Medicine Review

Issue

Vol 15, No 1 (2012)

Pages

61-70

Published online

2012-04-24

Bibliographic record

Nucl. Med. Rev 2012;15(1):61-70.

Keywords

cardiac sympathetic innervation
scintigraphy
iodine-123 metaiodobenzylguanidine
MIBG

Authors

Anna Teresińska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl